Myasthenia gravis and community-acquired pneumonia: therapeutic challenges.

ABSTRACT: Myasthenia gravis (MG) patients are highly susceptible to community-acquired pneumonia (CAP) due to the need for immunosuppressive therapies and aspiration risks, with CAP representing the leading infectious cause of mortality in this population. The intersection of MG and CAP poses unique challenges for the management of anti-infective agents and immunosuppressants. There is currently no systematic literature review addressing these issues, as previous reviews have been limited to one of these aspects. This review synthesizes evidence on the pharmacotherapeutic challenges associated with MG-CAP comorbidity, focusing on three key areas: avoiding antibiotics that exacerbate neuromuscular junction symptoms, minimizing drug interactions, and managing infection-adjusted immunosuppressants. Thr

SUBMITTER: Chen X 

PROVIDER: S-EPMC12657373 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature